These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 4117647

  • 41. Psychosis and other psychiatric manifestations of levodopa therapy.
    Celesia GG, Barr AN.
    Arch Neurol; 1970 Sep; 23(3):193-200. PubMed ID: 5456717
    [No Abstract] [Full Text] [Related]

  • 42. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H.
    Wien Med Wochenschr; 1973 Jun 30; 123(26):433-5. PubMed ID: 4578743
    [No Abstract] [Full Text] [Related]

  • 43. Levodopa and depression in parkinsonism.
    Lehmann J.
    Lancet; 1971 Jan 16; 1(7690):140. PubMed ID: 4099634
    [No Abstract] [Full Text] [Related]

  • 44. Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
    Holden EM, Brody JA, Chase TN.
    Neurology; 1974 Mar 16; 24(3):263-5. PubMed ID: 4855953
    [No Abstract] [Full Text] [Related]

  • 45. [The therapeutic effect of L-dopa].
    Groneberg P, Struppler A.
    Naturwissenschaften; 1972 Nov 16; 59(11):492-6. PubMed ID: 4657650
    [No Abstract] [Full Text] [Related]

  • 46. [Treatment of Parkinson's disease with L-dopa. 77 cases].
    Boudin G, Castaigne P, Lhermitte F, Beck H, Guillard A, Marteau R, Pepin B, Rondot P, Raphy B.
    Rev Neurol (Paris); 1970 Feb 16; 122(2):89-102. PubMed ID: 4931719
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
    Kastin AJ, Barbeau A.
    Can Med Assoc J; 1972 Dec 09; 107(11):1079-81. PubMed ID: 4640811
    [Abstract] [Full Text] [Related]

  • 52. A double-blind controlled study of MK-486 in Parkinson's disease.
    Schwartz AM, Olanow CW, Spencer A.
    Trans Am Neurol Assoc; 1973 Dec 09; 98():301-3. PubMed ID: 4594189
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Amine precursors in neurologic disorders and the psychoses.
    Klawans H.
    Res Publ Assoc Res Nerv Ment Dis; 1975 Dec 09; 54():259-76. PubMed ID: 130667
    [No Abstract] [Full Text] [Related]

  • 56. Coupling of hypotensive and anit-Parkinson effects with two dopaminergic drugs.
    Düby SE, Dahl LK, Cotzias GC.
    Trans Assoc Am Physicians; 1971 Dec 09; 84():289-96. PubMed ID: 5164305
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF.
    Pullar IA, Dowson JH, Ahmed R, Chow R, Gillingham FJ.
    Confin Neurol; 1972 Dec 09; 34(2):143-8. PubMed ID: 4666057
    [No Abstract] [Full Text] [Related]

  • 60. What to do when Sinemet fails: Part one.
    Klawans HL.
    Clin Neuropharmacol; 1984 Dec 09; 7(2):121-33. PubMed ID: 6733692
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.